Is it time for BRCA1/2 mutation screening in the general adult population?: Impact of population characteristics

Genetics in Medicine

Volumn 17, Issue 1, 2015, Pages 24-26

  Palomaki, Glenn E ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL CONSUMPTION; BRCA2 GENE; BREAST CANCER; CANCER INCIDENCE; CANCER SCREENING; GENE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; NEXT GENERATION SEQUENCING; NOTE; ORAL CONTRACEPTIVE USE; OVARY CANCER; PENETRANCE; POPULATION; REPRODUCTIVE HISTORY; RISK FACTOR; SCREENING TEST; TUMOR SUPPRESSOR GENE; UNITED STATES; ADULT; BREAST NEOPLASMS; FEMALE; GENETICS; MASS SCREENING; MUTATION; OVARIAN NEOPLASMS;

ADULT; BREAST NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC TESTING; HUMANS; MASS SCREENING; MUTATION; OVARIAN NEOPLASMS;

EID: 84920532181     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2014.167     Document Type: Note

References (11)

1. Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci USA 2014;111:14205-14210.
2. King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 2014;312:1091-1092.
3. American Cancer Society. Cancer Facts and Figures 2014. Atlanta. http://www. cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Accessed 2 October 2014.
4. US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143:355-361.
5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2014. Jenkintown, PA, 2014.
6. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
7. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792.
8. Wald N, Cuckle H. Reporting the assessment of screening and diagnostic tests. Br J Obstet Gynaecol 1989;96:389-396.
9. Haddow JE, Palomaki GE. An introduction to assessing genomic screening and diagnostic tests. Nutr Today 2011;46:162-168.
10. McClain MR, Palomaki GE, Nathanson KL, Haddow JE. Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. Genet Med 2005;7:28-33.
11. McClain MR, Nathanson KL, Palomaki GE, Haddow JE. An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. Genet Med 2005;7:34-39.